Summary

for people ages 18-99 (full criteria)
at UCLA
study started
estimated completion

Description

Summary

This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.

Official Title

A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors

Keywords

Advanced Solid Tumors durvalumab tremelimumab Neoplasms Antibodies, Monoclonal MEDI4736 MEDI4736 + Tremelimumab

Eligibility

You can join if…

Open to people ages 18-99

  • Male and female subjects
  • 18 years and older
  • Histologic confirmation of advanced solid tumors
  • Subjects must have recurrent/metastatic disease and may have been previously treated in the recurrent/metastatic setting.

You CAN'T join if...

  • Any concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatment
  • Active or prior documented autoimmune disease within the past 2 years
  • Current or prior use of immunosuppressive medication within 14 days with some exceptions.

Locations

  • Research Site
    Los Angeles California 90095 United States
  • Research Site
    Los Angeles California 90025 United States
  • Research Site
    La Jolla California 92093 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MedImmune LLC
ID
NCT02261220
Phase
Phase 1
Study Type
Interventional
Last Updated